For FY2024, Roche Bobois SA will propose, at the next Annual General Meeting to be held on June 12, 2025, a dividend of 1.25 € per share, which corresponds to 80% of net income. For FY2025, Roche ...

Castles are made for infiltrating in Assassin's Creed Shadows. Trust me - you're going to be visiting a lot of them during your time in Japan! Whether you're looking for resources to smuggle, new ...

Roche and its Genentech subsidiary are planning to hitch up their cardiovascular, renal and metabolism R&D work and shift it over to a new center in Harvard’s Enterprise Research Campus.

Swiss pharmaceutical company Roche announced Friday it will open an innovation center in the Harvard University Enterprise Research Campus in Allston that could employ hundreds. The Roche ...

However, nestled in the English countryside is a village so enchanting that it rivals the beauty of Switzerland - without the hefty price tag. Castle Combe, located in the Cotswolds, is often ...

Takatsuki Castle in Assassin's Creed Shadows is filled with enemies, but there's a legendary loot chest just waiting to be found and opened. Like most other Assassin's Creed Shadows Castles ...

Today, Roche is headquartered in Basel, Switzerland. The company now employs 80,000 people across a number of pharmaceutical and diagnostic sites across the world. The first of many successes ...

Roche Castle is one of the most impressive Anglo Norman castles in Ireland. Situated 7km north west from Dundalk, its hilltop location offers spectacular views of the surrounding countryside.

Basel, March 7, 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY), announced today the launch of the Roche Genentech Innovation Center Boston at Harvard’s Enterprise Research Campus in Allston which ...

Roche Holding AG hired a senior executive from rival Novo Nordisk A/S as the Swiss drugmaker prepares to enter the hyper-competitive market for obesity drugs. Morten Lammert will join Roche as its ...

Data from a phase 2 trial of Roche's oral BTK inhibitor fenebrutinib have shown "near-complete suppression" of disease activity and disability progression in relapsing multiple sclerosis (MS).